A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.

Also called NCT01200394

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 256 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01200394
  • EudraCT 2010-021358-20
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Denmark, Hong Kong SAR China, India, Malaysia, Mexico, Poland, Serbia, Slovakia, South Africa, South Korea, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01200394. Randomized; double masking; primary purpose treatment. Start 2010-12 (actual); primary completion 2013-07 (actual). Results posted on 2019-03-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
Condition
Diabetic Nephropathies
Intervention (Drug)
PF-00489791
Intervention (Drug)
Placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01200394
Content hash
8c6450012a7e4cce207b24310b834a4cbb518b80c6412293436835ba681c3ab3